Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356200 · ClinicalTrials.gov registry record · Phase 2
Fluphenazine Decanoate for Psoriasis
A Phase 2 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00356200 is a Phase 2 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00356200, a Phase 2 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test tubes. Its usefulness and safety in people with psoriasis will be investigated in this study.
Interventions
- DRUG Placebo
- DRUG Fluphenazine Decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356200
The ClinicalTrials.gov registry entry for NCT00356200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00356200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356200 about?
NCT00356200 is a clinical study titled "Fluphenazine Decanoate for Psoriasis". We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms...
What is the current status of trial NCT00356200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00356200?
The interventions under investigation include: Placebo (DRUG), Fluphenazine Decanoate (DRUG).
Who is sponsoring clinical trial NCT00356200?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.